RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM

Samuel Z. Goldhaber; John Heit; G. V.R.K. Sharma; J. Stevan Nagel; Ducksoo Kim; J. Anthony Parker; David Drum; Kathleen Reagan; James Anderson; Craig M. Kessler; John Markis; Douglas Dawley; Michael Meyerovitz; Douglas E. Vaughan; Sabah S. Tumeh; Joseph Loscalzo; Andrew P. Selwyn; Eugene Braunwald

doi:10.1016/S0140-6736(88)92354-9

RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM

Samuel Z. Goldhaber, John Heit, G. V.R.K. Sharma, J. Stevan Nagel, Ducksoo Kim, J. Anthony Parker, David Drum, Kathleen Reagan, James Anderson, Craig M. Kessler, John Markis, Douglas Dawley, Michael Meyerovitz, Douglas E. Vaughan, Sabah S. Tumeh, Joseph Loscalzo, Andrew P. Selwyn, Eugene Braunwald

Cardiovascular Medicine

Research output: Contribution to journal › Article › peer-review

271 Scopus citations

Abstract

The effect of intravenous recombinant human tissue-type plasminogen activator (rt-PA) was compared with that of urokinase in 45 patients with angiographically documented pulmonary embolism (PE) in a randomised controlled trial. The two principal end-points were clot lysis at 2 h, as assessed by angiography, and pulmonary reperfusion at 24 h, as assessed by perfusion lung scanning. All patients received the full dose of rt-PA but urokinase infusions were terminated prematurely (on average after 18 h) in 9 patients because of allergy in 1 and uncontrollable bleeding in 8. By 2 h, 82% of rt-PA-treated patients showed clot lysis, compared with 48% of urokinase-treated patients (p=0·008; 95% CI for the difference = 10-58%). Improvement in lung scan reperfusion at 24 h was identical in the two treatment groups. The reduction in fibrinogen did not differ significantly between the rt-PA and urokinase groups (45% vs 39% at 2 h and 34% vs 40% at 24 h). The results indicate that in the dose regimens employed, rt-PA acts more rapidly and is safer than urokinase in the treatment of acute PE.

Original language	English (US)
Pages (from-to)	293-298
Number of pages	6
Journal	The Lancet
Volume	332
Issue number	8606
DOIs	https://doi.org/10.1016/S0140-6736(88)92354-9
State	Published - Aug 6 1988

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0140-6736(88)92354-9

Cite this

Goldhaber, S. Z., Heit, J., Sharma, G. V. R. K., Nagel, J. S., Kim, D., Parker, J. A., Drum, D., Reagan, K., Anderson, J., Kessler, C. M., Markis, J., Dawley, D., Meyerovitz, M., Vaughan, D. E., Tumeh, S. S., Loscalzo, J., Selwyn, A. P., & Braunwald, E. (1988). RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM. The Lancet, 332(8606), 293-298. https://doi.org/10.1016/S0140-6736(88)92354-9

Goldhaber, SZ, Heit, J, Sharma, GVRK, Nagel, JS, Kim, D, Parker, JA, Drum, D, Reagan, K, Anderson, J, Kessler, CM, Markis, J, Dawley, D, Meyerovitz, M, Vaughan, DE, Tumeh, SS, Loscalzo, J, Selwyn, AP & Braunwald, E 1988, 'RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM', The Lancet, vol. 332, no. 8606, pp. 293-298. https://doi.org/10.1016/S0140-6736(88)92354-9

@article{61588fe7cc06408fbf134c14d601f72d,

title = "RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM",

abstract = "The effect of intravenous recombinant human tissue-type plasminogen activator (rt-PA) was compared with that of urokinase in 45 patients with angiographically documented pulmonary embolism (PE) in a randomised controlled trial. The two principal end-points were clot lysis at 2 h, as assessed by angiography, and pulmonary reperfusion at 24 h, as assessed by perfusion lung scanning. All patients received the full dose of rt-PA but urokinase infusions were terminated prematurely (on average after 18 h) in 9 patients because of allergy in 1 and uncontrollable bleeding in 8. By 2 h, 82% of rt-PA-treated patients showed clot lysis, compared with 48% of urokinase-treated patients (p=0·008; 95% CI for the difference = 10-58%). Improvement in lung scan reperfusion at 24 h was identical in the two treatment groups. The reduction in fibrinogen did not differ significantly between the rt-PA and urokinase groups (45% vs 39% at 2 h and 34% vs 40% at 24 h). The results indicate that in the dose regimens employed, rt-PA acts more rapidly and is safer than urokinase in the treatment of acute PE.",

author = "Goldhaber, {Samuel Z.} and John Heit and Sharma, {G. V.R.K.} and Nagel, {J. Stevan} and Ducksoo Kim and Parker, {J. Anthony} and David Drum and Kathleen Reagan and James Anderson and Kessler, {Craig M.} and John Markis and Douglas Dawley and Michael Meyerovitz and Vaughan, {Douglas E.} and Tumeh, {Sabah S.} and Joseph Loscalzo and Selwyn, {Andrew P.} and Eugene Braunwald",

year = "1988",

month = aug,

day = "6",

doi = "10.1016/S0140-6736(88)92354-9",

language = "English (US)",

volume = "332",

pages = "293--298",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "8606",

}

TY - JOUR

T1 - RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM

AU - Goldhaber, Samuel Z.

AU - Heit, John

AU - Sharma, G. V.R.K.

AU - Nagel, J. Stevan

AU - Kim, Ducksoo

AU - Parker, J. Anthony

AU - Drum, David

AU - Reagan, Kathleen

AU - Anderson, James

AU - Kessler, Craig M.

AU - Markis, John

AU - Dawley, Douglas

AU - Meyerovitz, Michael

AU - Vaughan, Douglas E.

AU - Tumeh, Sabah S.

AU - Loscalzo, Joseph

AU - Selwyn, Andrew P.

AU - Braunwald, Eugene

PY - 1988/8/6

Y1 - 1988/8/6

N2 - The effect of intravenous recombinant human tissue-type plasminogen activator (rt-PA) was compared with that of urokinase in 45 patients with angiographically documented pulmonary embolism (PE) in a randomised controlled trial. The two principal end-points were clot lysis at 2 h, as assessed by angiography, and pulmonary reperfusion at 24 h, as assessed by perfusion lung scanning. All patients received the full dose of rt-PA but urokinase infusions were terminated prematurely (on average after 18 h) in 9 patients because of allergy in 1 and uncontrollable bleeding in 8. By 2 h, 82% of rt-PA-treated patients showed clot lysis, compared with 48% of urokinase-treated patients (p=0·008; 95% CI for the difference = 10-58%). Improvement in lung scan reperfusion at 24 h was identical in the two treatment groups. The reduction in fibrinogen did not differ significantly between the rt-PA and urokinase groups (45% vs 39% at 2 h and 34% vs 40% at 24 h). The results indicate that in the dose regimens employed, rt-PA acts more rapidly and is safer than urokinase in the treatment of acute PE.

AB - The effect of intravenous recombinant human tissue-type plasminogen activator (rt-PA) was compared with that of urokinase in 45 patients with angiographically documented pulmonary embolism (PE) in a randomised controlled trial. The two principal end-points were clot lysis at 2 h, as assessed by angiography, and pulmonary reperfusion at 24 h, as assessed by perfusion lung scanning. All patients received the full dose of rt-PA but urokinase infusions were terminated prematurely (on average after 18 h) in 9 patients because of allergy in 1 and uncontrollable bleeding in 8. By 2 h, 82% of rt-PA-treated patients showed clot lysis, compared with 48% of urokinase-treated patients (p=0·008; 95% CI for the difference = 10-58%). Improvement in lung scan reperfusion at 24 h was identical in the two treatment groups. The reduction in fibrinogen did not differ significantly between the rt-PA and urokinase groups (45% vs 39% at 2 h and 34% vs 40% at 24 h). The results indicate that in the dose regimens employed, rt-PA acts more rapidly and is safer than urokinase in the treatment of acute PE.

UR - http://www.scopus.com/inward/record.url?scp=0023752733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023752733&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(88)92354-9

DO - 10.1016/S0140-6736(88)92354-9

M3 - Article

C2 - 2899718

AN - SCOPUS:0023752733

SN - 0140-6736

VL - 332

SP - 293

EP - 298

JO - The Lancet

JF - The Lancet

IS - 8606

ER -

RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this